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Abstract
In this paper we study approaches for dealing with treatment when developing a clinical prediction model. Analogous to the 
estimand framework recently proposed by the European Medicines Agency for clinical trials, we propose a ‘predictimand’ 
framework of different questions that may be of interest when predicting risk in relation to treatment started after baseline. 
We provide a formal definition of the estimands matching these questions, give examples of settings in which each is useful 
and discuss appropriate estimators including their assumptions. We illustrate the impact of the predictimand choice in a 
dataset of patients with end-stage kidney disease. We argue that clearly defining the estimand is equally important in predic-
tion research as in causal inference.
Keywords Clinical prediction model · Treatment · Censoring · Estimands · Predictimands
Introduction
Clinical prediction models provide individualized prognostic 
information that can be used to counsel patients about the 
likely course of their disease. Prediction models can also 
support treatment decisions. For instance, if a patient’s risk 
of a poor outcome in the next year is relatively low, then she 
or he may not need treatment. If the risk of a poor outcome 
is high, additional preventive or curative treatments should 
be considered [1]. But what is exactly meant by “a patient’s 
prognosis” or “a patient’s risk” here? Do we mean the risk 
assuming that no treatment is given, the risk under current 
standard treatment, the risk of experiencing the event in the 
time period before being treated, or something else? An 
increasing number of clinical prediction models are becom-
ing available through websites and apps. However, for many 
of these models it is unclear how the risk they aim to capture 
relates to treatment.
The data sources used for the development of clinical 
prediction models often contain data on a mix of patients 
who did and did not receive treatments that affect the risk of 
the event of interest. This holds both for observationally col-
lected data and for trial data. Completely untreated cohorts 
can sometimes be found in historical data collections, but 
these cohorts are rare and may not be relevant to current 
practice in other important ways. Using data solely from 
untreated patients can also lead to highly selected cohorts 
that are not generalizable. Dealing with treated patients is 
thus a challenge that needs to be addressed when develop-
ing a clinical prediction model. Baseline treatments can 
be included as predictors when developing, or externally 
validating, a prediction model, meaning that for a new 
patient the model can be used to predict the outcome, pro-
vided information is available about baseline treatment sta-
tus and other predictors [2]. However, for treatments that 
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are initiated after baseline, there is no easy solution, nor 
is there a single question of interest [3]. We do not know 
at baseline what treatments will be initiated later on and 
we cannot use future values as predictors. Moreover, the 
way treatments are dealt with during model development 
will have impact on how predictions can be used in future 
patients. Currently, ad hoc approaches are used where treat-
ment initiation may be ignored, patients are censored at the 
moment they start or switch treatment, or even excluded 
completely from the development cohort. Such analysis 
choices are often reported as mere technical analysis issues 
[4], but they may have a major impact on interpretation. 
The predictions resulting from such approaches might end 
up targeting a different risk than researchers intended. For 
example, censoring patients when they receive a transplan-
tation when estimating survival among patients listed for 
liver transplantation has shown to overestimate the actual 
observed waiting list mortality [5, 6]. The TRIPOD report-
ing guideline on development and validation of prediction 
models offers hardly advice on the issue. The only related 
point on the TRIPOD checklist is that one should describe 
the treatments that patients received, if relevant (item 5c) 
[7].
The European Medicines Agency (EMA) has recently 
released a new guideline that provides a framework to deal 
with additional treatments started after baseline and other 
so-called intercurrent (post-baseline but pre-outcome) events 
in the context of clinical trials: the addendum to the ICH E9 
guideline Statistical Principles for Clinical Trials [8]. The 
guideline distinguishes five possible strategies: a ‘treatment 
policy’ strategy that follows the intention-to-treat princi-
ple and ignores any change in treatment after baseline, a 
‘composite’ strategy that includes the start of an additional 
treatment as part of the outcome definition, a ‘hypotheti-
cal’ strategy that aims to assess the outcome in a scenario 
where no additional treatment would be given, a ‘principal 
stratum’ strategy where the outcome is considered in a cer-
tain subset of patients who would never start the additional 
treatment independent of their allocated treatment, and a 
‘while on treatment’ strategy where the outcome is assessed 
in the time period up until the additional treatment is started. 
Together with the definition of the population, the outcome 
of interest and the effect measure, each strategy defines an 
estimand which is the target quantity that the trialists aim to 
estimate. Each estimand represents a different causal ques-
tion. In the trial context, these questions relate to treatment 
effects. In prediction models, the aim is to assess patients’ 
expected outcomes conditional on certain patient character-
istics measured at baseline. We argue that, just like in trials, 
the quantity that a clinical prediction model targets should be 
unequivocally defined. Therefore we map the E9 estimand 
framework to the context of prediction models, proposing a 
predictimand1 framework.
Our focus in this manuscript is on prognosis over time, 
so on time-to-event or failure-time outcomes. We consider 
treatments that are initiated during follow-up. Previous stud-
ies on estimands in prediction research considered point 
(time-invariant) treatments [2] and binary outcomes [3]. 
Recently, Pajouheshnia and colleagues discussed analy-
sis methods for time-to-event prediction of untreated risk 
in the presence of time-dependent treatment [9]. Here we 
will extend that work by considering different questions 
that can be assessed by prediction models and that will be 
of interest in different applied settings. We formulate these 
strategies analogous to the trial estimand framework from 
the E9 addendum. We provide a formal definition of the 
prediction estimands matching these questions. For each of 
the estimands, we discuss key assumptions for estimation 
and list common estimators. We illustrate the impact of the 
predictimand choice in a dataset of patients with end-stage 
kidney disease.
Notation
To simplify, we consider only one treatment (A) that is 
related to the event of interest. Patients are all event-free 
and without this treatment at time zero. At that moment we 
collect baseline covariates X(0), which will be used to deter-
mine the prognosis of the patient. T is the time to the event of 
interest. Some patients will start treatment A over time, with 
V the time to treatment start and A(t) the time dependent 
treatment indicator. In principle, A(t) could switch between 0 
(no treatment) and 1 (treatment) multiple times over the fol-
low up, but, to enhance readability, in the following we will 
assume that once patients initiated treatment, they stay in the 
treated condition throughout. For patients who experience 
the event of interest before treatment start, V is latent. Both 
T and V can be censored by end of study or loss to follow up 
which we assume for simplicity to be non-informative cen-
soring mechanisms, conditional on baseline covariates X(0). 
In some studies, patients are no longer followed for the event 
of interest after treatment initiation, for instance in a registry 
of patients on dialysis that no longer follows patients after a 
kidney transplantation. This situation is depicted in Fig. 1a. 
If follow up on the event of interest does continue after a 
new treatment is initiated, we are in the setting depicted 
in Fig. 1b. The two figures are not causal directed acyclic 
graphs, but could be viewed as state transition diagrams of 
1 We chose the term ‘predictimand’ as a portmanteau of ‘prediction’ 
and ‘estimand’. Another term that could be used in this context is pre-
dictant, whereas predicand or predicend might better follow the rules 
of Latin grammar.
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a multistate model [10]. Figure 1a is similar to a competing 
risks setting and Fig. 1b is similar to that of an illness death 
model, with the intermediate state in our case not disease 
but treatment. The pace at which patients initiate treatment 
is denoted by the transition intensity 훼(t,H
t
) , where H
t
 is the 
history of the patient up to time point t. Later on, we will 
distinguish between situations where the treatment decisions 
are only based on patients’ baseline prognostic covariates, 
i.e., H
t
= {X(0)} and situations where the treatment deci-
sions are also based on prognostic markers that evolve over 
time, i.e., H
t
= {X(s);s ≤ t}.
Predictimands
Below we describe four strategies for how to deal with treat-
ment initiation after baseline in the development of a predic-
tion model. We formulate the interpretation of the resulting 
prediction estimands, give examples of settings where they 
are useful and discuss how they apply to new patients that 
were not used for development of the predictions, i.e., their 
generalizability [11]. The four strategies described have 
analogous estimands in the E9 addendum. The fifth -prin-
ciple stratum- estimand described in the addendum was not 
mapped to the prediction setting as it refers to a counterfac-
tual subpopulation that has no immediate analogue to the 
prediction setting. In the “Estimators and their assumptions” 
section we focus on assumptions needed for estimation of 
the predictimands and list some common estimators. An 
overview is presented in Table 1.
a
Event-free Event of interest
Treatment A
α(t
, H
t)
b
Event-free Event of interest
Treatment A
α(t
, H
t)
Fig. 1  Graphical representation of the studied situation. Follow up on 
the event of interest may stop (a) or continue (b) after treatment ini-
tiation
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“Ignore treatment” strategy
In this strategy, treatment initiation is considered part of 
standard practice. The value for T, the time to event of inter-
est, is used regardless of whether patients start treatment or 
not. So V, the time to treatment, is not used in any way. This 
is analogous to the “treatment policy” strategy in the E9 
guideline [8]. It has also been described as “simply ignore 
treatment” [2]. The risk that is estimated equals:
i.e., the risk of the event of interest occurring before a time 
horizon thor under the treatment practice inherent to the 
development dataset. An example of where this strategy was 
used, is in the development of QRISK3, a risk prediction 
algorithm that targets a person’s risk of a heart attack or 
stroke over the next 10 years [12]. The algorithm was devel-
oped using individuals who did not use statins at baseline, 
but statin use after baseline was ignored, as discussed in [3]. 
The calculated risks therefore belong to a population where 
some individuals will receive statins during follow up. The 
algorithm will only be generalizable to new patient groups 
if in those groups the same treatment assignment policy is 
used as in the development cohort. This implies that for all 
subgroups defined by the predictors in the prediction model, 
a similar proportion of patients should initiate treatment as 
in the development set. Provided the treatment is effective in 
reducing the risk of the outcome, the risk calculated with the 
“ignore treatment” strategy will be lower than the untreated 
risk, that is, the risk for a patient who will not be treated dur-
ing follow-up. If the ignore treatment predictimand is falsely 
interpreted as untreated risk and used for future decisions on 
prescribing (statins), it will underestimate the true untreated 
risk and this could lead to undertreatment in new patients 
[13]. The “ignore treatment” strategy requires continued fol-
low up after treatment initiation, so it cannot be used in the 
study design depicted in Fig. 1a.
“Composite” strategy
In the second strategy, treatment is combined into a com-
posite outcome together with the event of interest. In such a 
“composite” strategy we target
i.e., the risk of the event of interest or the treatment occur-
ring before time thor . In this strategy the treatment is inte-
grated in the clinical outcome. An example is predicting 
the composite of cardiovascular death, myocardial infarc-
tion and treatment with revascularisation (PCI or surgery) 
[14]. Including the treatment in the outcome may seem a 
somewhat artificial way of dealing with treatment and may 
(1)P(T ≤ thor|X(0)),
(2)P(min(T ,V) ≤ thor|X(0)),
lead to a less well interpretable outcome, but some use 
cases exist. A “composite” strategy can for instance be used 
when the treatment has very likely prevented an imminent 
occurrence of the event of interest and treatment can be 
viewed as a proxy of the event (i.e., without PCI or surgery 
a patient would develop a myocardial infarction). Other set-
tings where a composite outcome can be useful is when a 
poor outcome is more clearly captured by its consequence 
of needing treatment than by giving a precise description of 
poor health status. For example, Von Dadelszen et al. [15] 
used a composite outcome including amongst others receiv-
ing infusion of a third parental hypertensive drug, intuba-
tion, transfusion with any blood product and dialysis, when 
predicting severe maternal outcomes in pre-eclampsia. A 
third use case for the composite strategy is predicting the 
chances of a good outcome (one minus composite) defined 
as staying event-free without requiring additional treatment. 
The “composite” strategy does not need continued follow up 
after treatment initiation. Applying a composite prediction 
estimand to new patients requires similar treatment assign-
ment policies as in the development cohort. For instance, if 
in the new setting where the predictions are applied, patients 
in a certain subgroup are treated more often than similar 
patients in the development cohort, then the predictions of 
the combined outcome will be lower than the true probabili-
ties in that subgroup (miscalibration).
“While untreated” strategy
In the “while untreated” strategy, we are only interested in 
the event of interest if it happens before treatment is started. 
Events occurring after treatment start do not count as events. 
We target the risk of the event of interest occurring before 
time t
hor
 and before treatment is started.
This prediction estimand is well-known from competing 
risks analysis. It is often referred to as cumulative incidence. 
Starting treatment is then considered a competing event that 
precludes observing the untreated event of interest. Cumula-
tive incidence has also been referred to as the absolute risk, 
actual risk, crude probability, crude cumulative incidence 
function, absolute cause-specific risk or subdistribution 
function [16, 18, 19]. It has recently been conceptualized 
as the “risk without elimination of competing events” [17]. 
The analogous name for this strategy in the E9 addendum 
is “while on treatment”, referring to the response of the 
patient during the period where patients are still on their 
originally assigned treatment. Note that what distinguishes 
this strategy from the “ignore treatment” strategy is that at 
the moment treatment is started, the event of interest will by 
definition not occur anymore. An example is estimating the 
(3)P(T ≤ thor, T < V|X(0)).
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risk of dying while on the waiting list for a liver transplant 
[5]. Typically this strategy will be of interest if the treatment 
is not freely available, but limited due to waiting lists or 
other logistical constraints. Also for this strategy, predictions 
on new patients are only well calibrated if the assignment 
policy of treatment is similar to the development cohort. If 
in the application setting a subgroup is treated more often 
or sooner than in the development set, the predictions will 
overestimate the true “while untreated” risk in this subgroup.
“Hypothetical” strategy
In this strategy we envision a world where treatment does 
not exist. We aim to estimate the untreated risk before time 
thor:
where Tv=∞ represents the counterfactual time to the event 
of interest if V is set to infinity, i.e., in a hypothetical world 
where treatment A is eliminated. Like the “while untreated” 
strategy, this strategy too has an analogue in the competing 
risk literature. Young et al. [17] refer to this risk as the “risk 
under elimination of competing events”. It has been referred 
to as the marginal cumulative incidence, net risk, or pure 
risk [18, 19]. The risk quantifies how likely the event of 
interest would be if nobody were to receive treatment. Since 
we are only interested in the risk up to thor , we could simi-
larly have used Tv>thor instead of Tv=∞ . In the E9 addendum 
this strategy is similarly referred to as the “hypothetical” 
strategy.
An example application is estimation of the ‘risk’ of a 
natural pregnancy without use of assisted reproductive tech-
niques such as IVF [20]. Other hypothetical scenarios (e.g., 
what if treatment is started after 1 year) could in principle 
also be targeted. In fact, if we could set v exactly according 
to the function that clinicians used in the development cohort 
to determine when to start treatment, this estimand would 
reduce to the “ignore treatment” estimand in (1). But here 
we only discuss the hypothetical untreated risk further. Esti-
mating the hypothetical untreated risk is challenging (more 
on this later), but, once constructed, it is readily generalis-
able to new patients when posing the question what would 
happen if the new patient is never treated. This untreated/
baseline risk is useful to inform decisions on treatment A. 
Note that the three other strategies (ignore treatment, com-
posite and while untreated) cannot be used to inform the 
decision to start treatment A, as this might lead to something 
that has been described as the ‘prediction paradox’: pre-
dictions influencing behaviours (i.e., treatment decisions) 
that in turn invalidate predictions [13]. These three predicti-
mands will be miscalibrated if the treatment decisions made 
in new patients differ from those in the development cohort.
(4)P(Tv=∞ ≤ thor|X(0)),
Estimators and their assumptions
In this section we focus on key assumptions and design ele-
ments that are necessary for estimating each predictimand. 
Without being exhaustive, we link the estimands to common 
estimators.
“Ignore treatment” strategy
Since in this strategy starting treatment after baseline is 
ignored, standard time to event regression methods may be 
used to relate the event of interest to the covariates X(0). For 
instance, one could use Cox regression models combined 
with the nonparametric Breslow (or Efron) estimator for the 
baseline hazard or flexible parametric survival models. The 
main assumption here is that of non-informative censoring 
for reasons like loss to follow up or end of study. Particu-
lar methods may additionally assume proportional hazards 
for the covariates. Note that since we do not censor at the 
moment of treatment start, this strategy requires continued 
follow up after treatment initiation.
“Composite” strategy
Also with this strategy the analysis is relatively straightfor-
ward and can be done with any chosen survival regression 
technique. Either occurrence of the event of interest or the 
occurrence of treatment counts as an event, whichever comes 
first. When one would use a Cox-like model, the assump-
tion of proportionality of covariate effects should hold for 
the composite outcome, which may be less likely than for 
single outcomes. Also, the non-informative censoring by 
loss to follow up or end of study should hold in relation to 
the composite outcome. Continued follow up after treatment 
initiation is not needed.
“While untreated” strategy
Estimation of cumulative incidence as expressed in (3) can 
be done with competing risks methods. Without covariates 
and without censoring for other reasons like loss to follow 
up or end of study, cumulative incidence is estimable by the 
number of patients with the event of interest divided by the 
total number of patients at baseline. With covariates and 
censoring for reasons like loss to follow up or end of study, 
the estimation can be done in various ways, see for instance 
[10, 21–24]. Continued follow up after treatment initiation 
is not needed.
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“Hypothetical” strategy
Estimation of (4) is challenging and relies on strong assump-
tions regarding the treatment assignment policy in the devel-
opment data. These assumptions are similar to those that are 
needed for identifying the causal treatment effect of A, which 
makes sense since the strategy implicitly imposes a counter-
factual or potential outcome version of A into the estimand of 
interest. Three key assumptions are required: exchangeabil-
ity, consistency and positivity [25]. The first one, exchange-
ability, is often the most challenging. It is sometimes called 
the ‘no unmeasured confounding’ assumption and requires 
that we have measured and appropriately corrected for (a 
sufficient subset of) the variables that both influenced the 
treatment decisions and are prognostic for the event of inter-
est [25]. This typically requires measuring time-dependent 
covariates since updated measurements of risk factors are 
very likely to influence treatment decisions. The second 
assumption, consistency, is often described as observed out-
comes being equal to counterfactual outcomes. It means that 
in the hypothetical world where treatment is eliminated, a 
patient’s untreated risk is the same as her or his untreated 
risk in the real world. If knowledge of the unavailability of 
treatment changes the risk behaviour of patients, this assump-
tion does not hold. This second assumption is typically not 
prohibitive; in some causal frameworks such changing risk 
behaviour is taken as a definition of the patient population 
[26]. The third assumption, positivity, means that we have 
observed a non-zero number of treated and untreated patients 
in our data for all covariate patterns during the time horizon 
that we want to use in our predictions (or have observed a 
sufficient number so as to smooth over gaps with modelling 
assumptions). For instance if all patients with a certain char-
acteristic are treated after 1 year, then we don’t have informa-
tion for estimating untreated outcomes beyond 1 year for such 
patients. It may well be that a shorter prediction horizon thor 
has to be chosen to fulfil the positivity assumption.
The analysis approach for the “hypothetical” strategy 
depends on how treatment decisions were made for the 
patients in the development data and on whether or not 
post-treatment follow up is used. Below, we sketch four 
analysis approaches. We first discuss two settings where it is 
assumed that in the development dataset treatment decisions 
were only based on baseline covariates X(0), i.e., prognos-
tic patient characteristics that are known at the moment we 
want to make the prediction. In most healthcare settings it 
is quite implausible that risk factor progression after base-
line doesn’t influence treatment decisions, but we include 
these options to indicate the limitations of common estima-
tion approaches. Then, we discuss two settings where risk 
factor progression is accounted for. There are two analysis 
approaches to target the hypothetical risk: we may stop fol-
low up when treatment is started, by censoring the time to 
event of interest at the moment treatment starts (Fig. 1a), or 
follow up data after the start of treatment may be included 
(Fig. 1b). As noted before, in some studies no follow up 
information is collected after treatment initiation, in which 
case only the censoring option remains. In the censoring 
approach positivity is only needed for untreated individuals, 
i.e., if for some covariate patterns no patients are treated, 
this is not per se a problem for estimating the untreated risk.
Several other estimation approaches than the ones 
described below have been proposed for the hypotheti-
cal untreated risk, each with their own assumptions. For 
instance using g-formula [17], copulas [27, 28] or multiple 
imputation [29, 30]. We refer to the mentioned references 
for further details on these methods.
Baseline covariates, censoring
In the situation sketched in Fig. 1a, time to event is censored 
at treatment start. The main assumption of this approach is 
that censoring by treatment is non-informative, conditional 
on the baseline prognostic covariates in the prediction model 
(X(0)). In other words, censoring the follow up at treatment 
start only gives a valid estimate of the hypothetical untreated 
risk if baseline prognostic factors that relate to treatment 
are included in the prediction model and treatment start is 
independent of changing values of prognostic markers dur-
ing follow-up, i.e., H
t
= {X(0)} . This is a strong and often 
implausible assumption that cannot be tested on the data. 
Such an assumption can only be verified with those who 
were responsible for the treatment decisions.
Baseline covariates, modelling
When follow up after treatment start is available, this fol-
low-up information can be used in the development of the 
prediction model. Treatment A can be added as an addi-
tional, time dependent, covariate to the prediction model. 
Then a prediction under the “hypothetical” strategy of no 
treatment can be obtained by setting A(t) = 0 for all t in the 
prediction horizon ( t ≤ thor ). This approach is valid under 
the same strong and often implausible assumption as the first 
approach that we described. Only in case treatment choices 
were solely based on collected prognostic baseline factors 
that are included in the prediction, the model including X(0) 
is sufficient to get an unconfounded estimate of the effect of 
A. There is a caveat to this approach of modelling the treat-
ment effect. The advantage of using a longer period of fol-
low up is at the expense of having to model the effect of the 
treatment on the event of interest. Therefore, the functional 
form of the treatment effect should be carefully chosen: the 
assumption of proportional hazards between the treated and 
untreated patients over time and the presence of possible 
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interactions between patient characteristics and treatment 
should be checked.
Time varying covariates, censoring
We now turn to the more realistic situation where time-vary-
ing prognostic patient characteristics have additionally influ-
enced the treatment decisions, i.e., H
t
= {X(s), s ≤ t} . For 
example when the condition of patients has been monitored 
by repeatedly measuring their blood values and these meas-
urements have influenced the decisions about treatment ini-
tiation. In the censoring case (Fig. 1a), inverse probability of 
censoring weighting (IPCW) could be used. This approach 
assumes that treatment start is independent of the future 
untreated risk conditional on baseline covariates X(0) and 
time dependent covariates X(t). X(t) is used to estimate time-
varying conditional probabilities of starting treatment. By 
assigning weights to patients that are inversely proportional 
to their conditional probability of not yet being treated, a 
weighted population is created that (under the assumptions 
of exchangeability, consistency and positivity) mirrors the 
pseudo-population that would have been observed in the 
absence of treatment [17, 31–34]. Applying inverse prob-
ability weighting when estimating a survival model for the 
event of interest with censoring at treatment start thus cor-
rects for the informative censoring related to X(t).
Time varying covariates, modelling
When post-treatment follow up is used to model the effect 
of treatment on the event of interest, adding both X(t) and 
A in the survival model similar to the “Baseline covariates, 
modelling” approach, will in the presence of time varying 
covariates not yield a useful prediction model, because for 
a new patient X(t) will not be known when predicting at 
baseline. The hypothetical untreated risk to estimate from 
Fig. 1b is similar to what is called the ‘controlled direct 
effect’ in mediation analysis, when setting treatment as the 
mediator at a fixed zero level (no treatment) [35]. A potential 
solution is to fit a marginal structural model with inverse 
probability of treatment weighting (IPTW) to break the link 
between X(t) and A(t) [36]. Using these weights, a model 
containing X(0), A(t) and potential interactions as predic-
tors can be fitted and one can estimate the hypothetical risk 
from this model setting A(t) = 0 . Details on implementing 
this approach for prediction modelling in both logistic and 
time-to-event models can be found in [3]. We again have to 
assume correct specification of the treatment effect.
Data application
In this section, we study the four proposed prediction esti-
mands in data from the Netherlands Cooperative Study on 
the Adequacy of Dialysis (NECOSAD) [37]. This study is 
a multicenter cohort study in which patients with end stage 
renal disease were included at dialysis initiation if they 
were 18 years or older and had no previous kidney trans-
plantation and no previous dialysis. The NECOSAD study 
was approved by the local medical ethics committees and 
all patients gave informed consent. Patients were followed 
until renal transplantation, death or end of study. Here we 
consider death the event of interest and renal transplantation 
is the treatment that may be initiated at some point in time 
after baseline. As in NECOSAD patients were not followed 
after renal transplantation, information on death after trans-
plantation was retrieved by linking the NECOSAD data to 
the Dutch registry of renal replacement therapy, RENINE 
(Registratie Nierfunctievervanging Nederland) [38]. Patients 
were included between 1997 and 2007, and followed until 
February 1, 2015. Patients who were not coded as deceased 
or lost to follow up in RENINE were assumed to be alive 
at end of follow up. Our initial data set contained n = 2051 
patients. We removed 6 patients with missing informa-
tion on age, yielding 2045 patients in our analysis. For 43 
patients who were still alive at the last follow up visit of 
the NECOSAD study, no link to the registry could be made 
and we censored time to death and, where applicable, time 
to transplantation for these patients at their last follow up 
in NECOSAD. The median time in follow up of the 2045 
patients was 5.1 years. In this period, 749 patients received 
a kidney transplant, 1470 patients died of whom 248 after 
transplantation. Age and baseline dialysis type (hemodialysis 
(HD) versus peritoneal dialysis (PD)) were used as baseline 
predictors of mortality (X(0)). With HD, blood is pumped 
out of the patient’s body and filtered by an artificial kid-
ney machine. With PD, cleansing fluid is pumped into the 
patient’s abdominal cavity and the lining of the abdomen 
acts as a natural filter to wash out waste and toxins. As this 
example is used for illustration purpose, we did not include 
more baseline variables in the prediction model. Addition-
ally, for estimating the hypothetical prediction estimand, we 
used the following time dependent covariates X(t) as pre-
dictors of treatment: Charlson comorbidity score, BMI and 
calcium blood values, which were measured at 6 months 
intervals. We estimated the mortality risk over a time span of 
10 years, given age (as a continuous variable) and baseline 
dialysis type. We used the packages survival, mstate, 
and ipw of the R statistical software [39]. Our analysis code 
along with a simulated dataset can be found in the Supple-
mentary Materials. The different predictimands were esti-
mated as follows:
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• The “ignore treatment” strategy targets the total mortality 
risk, regardless of whether patients did or did not receive 
a transplantation. For estimation, we used a Cox pro-
portional hazards model with the non-parametric base-
line hazard estimated using the approach proposed by 
Efron (further on referred to as Cox–Efron) [40]. Death 
was defined as the event, age and dialysis type as base-
line covariates and we censored the patients alive at the 
moment of last follow up. Note that for estimating the 
“ignore treatment” risk, follow up for death after trans-
plantation is needed, which was retrieved by linking the 
NECOSAD data to the Dutch Renal Registry.
• With the “composite” strategy, we estimate the risk of 
either dying or receiving a transplantation. To this end, 
transplantation and death were combined as composite 
event in a Cox–Efron analysis, again with age and dialy-
sis type as baseline covariates and censoring those alive 
at the moment of last follow up. Studying a composite 
outcome in this situation can be informative, e.g., for 
policy makers, to know how long patients will likely 
stay alive and without transplantation and thus remain 
on dialysis treatment. For estimating the “composite” 
risk, follow up after transplantation is not needed.
• The “while untreated” strategy assesses the risk of dying 
before receiving a transplantation. To estimate this risk, 
we fitted two cause-specific Cox–Efron models: one 
model with death as event, age and dialysis type as base-
line covariates and censoring at time of transplant or 
at moment of last follow up alive, and one model with 
transplant as event, age and dialysis type as baseline 
covariates and censoring at death and at last follow up 
alive. The two cause specific hazard models were used 
to obtain the cumulative incidence for death [10]. Fol-
low up after transplantation is not needed for the “while 
untreated” risk.
• In the “hypothetical” strategy we estimate the risk of 
dying if no transplantation is performed. We followed the 
four different estimation methods described in ““Hypo-
thetical” strategy” section.
• First, we fitted a Cox–Efron model for death, with 
age and dialysis type as baseline covariates and 
where event times were censored when the patient 
received a transplantation or at the end of follow up. 
This model was then used to predict the mortality 
risk over time. This approach assumes that the deci-
sions on transplantation were based only on on age 
and dialysis type. Follow up after transplantation is 
not needed in this case.
• Second, transplantation was included as a time-
dependent covariate in a Cox–Efron model with age 
and dialysis type as baseline covariates, again assum-
ing that only these two baseline covariates drove the 
transplantation decisions. To model the effect of 
transplantation correctly, we explored whether add-
ing interactions between transplantation and base-
line covariates improved the model, but it did not. 
Since the transplantation effect seemed to change 
over time, we used a time varying coefficient for 
treatment according to a step function (with jumps 
at 3 and 8 years, chosen by visual inspection of the 
Schoenfeld residual plot). The hypothetical untreated 
risk was then estimated by setting A(t) = 0 . For this 
second approach where the effect of transplantation 
is modelled, we needed the additional follow up of 
death after transplantation.
• Third, we repeated the first analysis where we cen-
sored at treatment start, now applying inverse prob-
ability weighting to correct for time-dependent 
covariates that might have additionally influenced 
the transplantation decisions. Stabilized weights 
were estimated based on two Cox–Efron models 
with transplantation as event: a denominator model 
including Charlson comorbidity score, BMI and 
calcium blood values as covariates and a numera-
tor model with only an intercept. Some missings 
occurred in the time dependent covariates and we 
performed a single imputation method for each using 
a linear mixed model with follow up time, age and 
dialysis type as fixed factors and a random intercept. 
For patients who did not have any measurement of 
these covariates (1 for Charlson score, 17 for BMI, 
83 for calcium), we imputed the median of the other 
patients.
• Fourth, we repeated the second analysis where we 
modelled the effect of transplantation, applying 
the same inverse probability weights as in the third 
approach.
In Fig. 2 the predicted 10 year mortality curves are pre-
sented for a patient of age 50 and for a patient of age 
70, both starting on hemodialysis. Each curve represents 
a different type of mortality risk. Several observations 
can be made from the curves. The risks obtained from the 
“composite” strategy are highest while the curves from 
the “while untreated” strategy were lowest for most of the 
follow up times. This is according to expectation as the 
“composite” strategy counts every transplanted patient 
as event, while the “while untreated” counts transplanta-
tion as non-event. The other two strategies infer that part 
of the transplanted patients will reach the event, either 
according to observed deaths after transplantation in the 
“ignore treatment” strategy, or according to what would 
be expected if these patients were not transplanted in the 
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“hypothetical strategy”. The fact that the “while untreated” 
strategy does not yield the lowest predictions at all times 
can be explained by the modelling assumptions (propor-
tionality of covariates is acting on different scales, com-
posite hazard versus cause specific hazard versus marginal 
hazard). The composite curves for 50 and 70 years-old 
were very similar because younger patients have a lower 
probability of dying but a higher probability of getting a 
transplantation. The four curves belonging to the “hypo-
thetical” strategy are higher than those from the “ignore 
treatment” strategy, indicating that the current transplan-
tation policy reduces mortality compared to a hypotheti-
cal scenario where nobody would receive a transplant. 
This is more apparent at age 50, since more patients are 
transplanted at that age. The curves for patients starting 
on peritoneal dialysis were very similar to the curves for 
hemodialysis and are therefore not shown.
Our focus is on the interpretation of the different pre-
diction estimands. Below we sketch how our results could 
be used in a fictitious conversation between a doctor and 
a patient of age 50 starting on hemodialysis. 
∙ Doctor: You have progressed to end stage renal disease, meaning 
your kidneys no longer function sufficiently. My advice would be to 
start hemodialysis
∙ Patient: What is my prognosis on hemodialysis?
∙ Doctor: If we did not perform kidney transplantations, our best esti-
mate is that 59–62% of patients your age would die within 10 years. 
(hypothetical)
∙ Patient: Ok, but what about my prognosis given that I may receive a 
kidney transplantation?
∙ Doctor: With availability and allocation of transplants like in recent 
years, about 43% of patients dies within 10 years. (ignore treat-
ment)
∙ Patient: So, will I get a transplant in time?
∙ Doctor: I cannot say, we need a matching donor and there is a 
waiting list. Again assuming that availability and allocation of 
transplants does not change, in the next 10 years, you have about 
34% chance of dying before getting a transplant. (while untreated)
∙ Patient: What are the chances I will survive for 10 years and still be 
on dialysis?
∙ Doctor: With unchanged transplant availability and allocation, you 
have a 5% chance to still be alive and without transplant in 10 years. 
(1 minus composite)
We note that our simplified model with only two predic-
tors is not meant for use in clinical practice. Also for sim-
plicity, we omitted to report uncertainty intervals around the 
predictions. This example serves as an illustration that the 
different strategies of handling treatment start after baseline 
answer different risk questions.
Discussion
Starting treatment after baseline is very common in risk 
prediction settings. We argue that the way treatment is dealt 
with should not be degraded to ‘just a technical analysis 
choice’. In fact, different strategies may yield very different 
risk predictions. If not dealt with up-front, the choice may 
sneak in by the choice of analysis rather than being identified 
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Fig. 2  Predicted mortality curves and 10  year mortality risks for 
patients aged 50 and 70 on hemodialysis. red: composite, green: 
while untreated/cumulative incidence, black: ignore treatment, solid 
blue: hypothetical—censor at treatment, dashed blue: hypothetical—
modelling treatment, dotted blue: hypothetical—censor at treatment 
+ IPW, dotdash blue: hypothetical—modelling treatment + IPW
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intentionally as the prediction estimand of interest. Deci-
sions about how one wants to handle treatment initiation 
should be prespecified, based on which interpretation of risk 
is most appropriate. In some cases, multiple questions may 
be of interest and therefore investigators may choose to esti-
mate more than one of the four predictimands we described 
here.
Being clear about the prediction question of interest in 
the context of post-baseline occurrences is not only impor-
tant for treatment initiation. Any post-baseline behaviour or 
event that may be modifiable could be considered in light of 
our proposed framework. For example, in the transplantation 
setting, another modifiable post-baseline event that could 
be considered is patients who stop dialysis due to recovery. 
(In our analyses patients were censored in case of ceasing 
dialysis due to recovery, implying we used the “hypotheti-
cal” strategy with respect to this event.)
A recent systematic review on prediction models for 
on-dialysis mortality identified 16 models studying time to 
death [37]. Five of these used the Cox model with censor-
ing at transplantation, implicitly targeting the “hypothetical” 
prediction estimand. None of these five studies explained 
the consequences of censoring on treatment start for the 
interpretation of the calculated risk, and none paid attention 
to the non-informative censoring assumption. Three other 
models included death after transplantation in their out-
come (“ignore treatment” strategy). Three studies excluded 
patients who received transplants after baseline from their 
analyses, leading to predictions that are not generalizable. 
Five did not write anything about how they dealt with trans-
plantation, essentially rendering risk numbers that cannot 
be interpreted.
Whereas causal inference research is typically strictly 
distinguished from prediction research [41], we show in our 
paper that when predicting in the presence of modifiable 
events after baseline such as treatment initiation, methods 
from both domains are needed. A causal inference model 
aims to quantify what the counterfactual or potential out-
comes of patients would be with and without an interven-
tion and infers a causal effect of intervention from that. A 
prediction model aims to provide correct predictions of an 
outcome given a set of prognostic factors that do not have 
to be causally related to the outcome. The “hypothetical” 
prediction estimand could be classified as a type of coun-
terfactual prediction, since we predict potential outcomes ‘if 
the world were different’, namely, if no one receives treat-
ment [41]. Several untestable assumptions are needed here. 
The other three prediction estimands give ‘real world’ pre-
dictions and can be estimated from a development dataset 
without untestable assumptions. However, when predicting 
for new patients using these three strategies, we assume that 
similar treatment assignment policies apply as in the devel-
opment cohort. This is also a very strong assumption that 
cannot be tested upfront. The prognostic factors used in a 
clinical prediction model do not have to be causally related 
to the outcome, however the predictions they render will 
only be valid if the treatment policies that patients to whom 
the prediction model is applied are (1) clearly defined in the 
prediction estimand and (2) similar as in the development 
cohort (except for the “hypothetical” strategy).
Our focus in this paper is on the role of treatment in 
clinical prediction models. We have sketched how different 
strategies of handling treatment lead to different prediction 
estimands. The definition of the role of treatment and other 
intercurrent events is necessary but not sufficient to define 
a prediction estimand. Other aspects that need to be defined 
are the target population/setting (e.g., patients with end stage 
renal disease), the relevant outcome with an appropriate time 
horizon (e.g, 10-year mortality) and a time-point at which 
the prediction will be made (e.g., at start of dialysis) [42].
Throughout the paper we have referred to a single treat-
ment and assumed that treated patients remained treated 
throughout follow up. Usually many types of treatment are 
relevant for patients. For instance, data used for the develop-
ment of a cardiovascular risk model may contain information 
on patients who start using statins, patients who start using 
antihypertensives or lipid lowering drugs, patients following 
a particular diet etc. Depending on the goal of the risk pre-
diction, a choice should be made as to how each is handled. 
Typically a mixture of approaches will be used. Many treat-
ments will be considered ‘care as usual’ with assignment 
policies that are considered stable over time and can be han-
dled as background according to the ‘ignore treatment’ strat-
egy. However, if for example the prediction model is aimed 
to input to the question of whether new patients should or 
should not be given statins, then a different strategy should 
be used for statins. For each treatment, an explicit choice 
should be made as to which prediction estimand is targeted 
and appropriate attention should be given to the necessary 
assumptions for estimating this. When only few patients 
are treated (e.g., due to a short prediction horizon) or when 
treatment effects are small relative to the effect of the other 
prognostic factors in the model, the numerical differences 
between the strategies will be less pronounced than in our 
transplantation example, but may still be relevant.
In case patients switch between ‘off’ and ‘on’ treatment 
multiple times during follow up, the definition and analysis 
approach of the “ignore treatment” and “hypothetical” strat-
egy can stay unchanged. An application of the “hypotheti-
cal” strategy in such an ‘on’ and ‘off’ switching situation is 
presented in [9]. In the “composite” strategy it seems most 
sensible to count the first occurrence of a treatment epi-
sode as an event, but recurrent event approaches could also 
be considered [43]. The definition of the “while untreated” 
strategy could be extended to represent the risk of the event 
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of interest during all untreated episodes, so not only up to the 
first treatment episode as in the current definition.
An aspect of prediction modelling that was not addressed 
in our paper is assessment of predictive performance, i.e., 
model validation. Standard methods to validation of pre-
dictions apply to the “ignore treatment” and “composite” 
predictimands. For the “while untreated” strategy, methods 
suitable for competing risks analyses are needed, see for 
instance [44–46]. Validating predictions generated with 
the “hypothetical” strategy is more involved since also in 
a validation dataset there will likely be patients who start 
treatment after baseline. Validation in such a setting may 
require similar assumptions and estimation techniques as 
during estimation of the hypothetical predictions [47]. This 
warrants further research.
There might be a trade-off between relevance of an esti-
mand and the assumptions that one is willing to make in 
order to produce it. Due to its strong and untestable assump-
tions some authors have argued against using a “hypotheti-
cal” estimand saying one can better ‘stick to this world’ [48]. 
We argue that the future use of the prediction model should 
drive the predictimand choice. One should start by defin-
ing a clear estimand before considering how to compute it. 
When there is much uncertainty on the used assumptions, 
sensitivity analyses could be performed to assess the degree 
of uncertainty in the predictions [49].
In any case, when using a prediction model in clinical 
care, the meaning of predictions presented to patients should 
be unequivocally clear. Our predictimand framework can 
help researchers explicating what risk is targeted by their 
model.
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